MedTrace Logo

Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

NCT05045053 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-09-16

No results posted yet for this study

Summary

dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

Conditions

  • Corneal Disease

Interventions

DRUG

Xiidra 5% Ophthalmic Solution

lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Tarek Elhamaky · Benha university faculty of medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05045053 on ClinicalTrials.gov